Bioavailability of Peptides

Introduction

Bioavailability—the proportion of administered peptide that reaches systemic circulation—is crucial for peptide efficacy. Understanding factors that influence bioavailability helps optimize peptide protocols.

Administration Routes

Route Comparison

Route	Bioavailability	Onset	Convenience
Intravenous	~100%	Immediate	Low
Subcutaneous	80-100%	15-30 min	High
Intramuscular	75-100%	10-20 min	Moderate
Oral	<1-2% (usually)	Variable	Highest
Nasal	Variable	Rapid	Moderate

Subcutaneous Considerations

Factor	Impact	Optimization
Injection site	Affects absorption rate	Abdomen often optimal
Volume	Large volumes slow absorption	Keep reasonable
Depth	Must reach subcutaneous fat	Proper technique

Factors Affecting Bioavailability

Chemical Properties

Factor	Effect	Examples
Molecular size	Larger = slower absorption	IGF-1 LR3 vs. GHRP
Charge	Affects membrane permeability	pH-dependent
Lipophilicity	Higher = better membrane crossing	Modified peptides
Stability	Degradation reduces availability	Prone vs. stable

Physiological Factors

Factor	Impact	Notes
Blood flow to site	Higher = faster absorption	Warm sites absorb faster
Tissue binding	May slow systemic availability	Can be beneficial
Enzymatic activity	Degrades peptides	Varies by location
Lymphatic drainage	Alternative absorption route	For larger peptides

Enhancing Bioavailability

Chemical Modifications

Modification	Purpose	Example
PEGylation	Extended half-life	Long-acting peptides
Albumin binding	Prolonged circulation	CJC-1295 DAC
D-amino acids	Protease resistance	Modified peptides
Cyclization	Increased stability	Cyclic peptides

Formulation Approaches

Strategy	Mechanism	Status
Absorption enhancers	Improve permeability	Research/clinical
Nanoparticle carriers	Protection + targeting	Development
Lipid formulations	Enhanced uptake	Some available

Oral Peptide Bioavailability

Barriers to Oral Delivery

Barrier	Challenge	Solutions
Gastric acid	Degradation	Enteric coating
Proteases	Enzymatic breakdown	Inhibitors, modifications
Intestinal membrane	Poor permeability	Enhancers
First-pass metabolism	Liver processing	Design modifications

Current Status

Peptide Type	Oral Availability	Notes
Small peptides	Some progress	Limited options
Larger peptides	Very challenging	Mostly experimental
Cyclic peptides	Better potential	Emerging technology

Practical Implications

Protocol Optimization

Goal	Approach	Implementation
Maximize absorption	Proper technique	Correct site, depth
Consistent levels	Regular timing	Establish routine
Reduce waste	Quality sourcing	Verified products

Timing Considerations

Factor	Recommendation	Rationale
Food intake	Fast for GH peptides	Insulin competition
Exercise	Post-workout optimal for some	Blood flow
Time of day	AM and pre-bed common	Natural GH rhythm

Conclusion

Understanding bioavailability helps optimize peptide use. While subcutaneous injection remains the standard, emerging technologies may expand options in the future.